Pharma channel feed

Eli Lil­ly ousts CFO Josh Smi­ley af­ter 'i­nap­pro­pri­ate re­la­tion­ship' with em­ploy­ee, ap­points suc­ces­sor in Anat Ashke­nazi

5 years ago
People

For­mer Gale­na chief Mark Ahn back in hot wa­ter as DOJ lev­els in­sid­er trad­ing charges for con­sul­tant work

5 years ago
People

Bris­tol My­ers Squibb earns long-await­ed FDA nod for liso-cel, join­ing short list of lym­phoma CAR-T win­ners

5 years ago
FDA+

FDA blasts Mer­ck­'s bid for ad­ju­vant Keytru­da in TNBC be­fore ad­comm, call­ing late-stage da­ta 'ques­tion­able'

5 years ago
FDA+

Re­gen­eron has a win­ner in Dupix­ent and big sales hopes. So why are so few pa­tients tak­ing it?

5 years ago

Sanofi flunks Parkin­son's Phase II, ax­es hand­ful of mid-stage pro­grams in Q4 earn­ings

5 years ago

Shift to dig­i­tal leaves hun­dreds of Am­gen sales jobs on chop­ping block

5 years ago

Mer­ck KGaA goes toe to toe with No­var­tis as FDA green-lights MET in­hibitor

5 years ago
FDA+

Year-end earn­ings show tur­bu­lent times for Hal Bar­ron's Glax­o­SmithK­line turn­around

5 years ago

Neu­ro­crine ax­es Parkin­son's col­lab with Voy­ager af­ter safe­ty is­sues, jeop­ar­diz­ing biotech's long-run­ning cen­ter­piece

5 years ago

#WCLC21: Mer­ck pokes Bris­tol My­ers in the eye with Keytru­da da­ta show­ing safe­ty red flags in Yer­voy com­bo tri­al

5 years ago

#WCLC21: As­traZeneca's EGFR in­hibitor Tagris­so cuts re­lapse, death risks in pa­tients with and with­out pri­or chemother­a­py

5 years ago

J&J her­alds 66% ef­fi­ca­cy for sin­gle-dose shot, but falls short of mR­NA ri­vals

5 years ago
Coronavirus

Drug­mak­ers 'inch­ing ahead' in in­creas­ing ac­cess to drugs world­wide, with Glax­o­SmithK­line lead­ing the pack

5 years ago

Lon­za look­ing to build on 'd­if­fer­en­ti­at­ed ad­van­tage' in Covid-19, CD­MO mar­ket­place in 2021

5 years ago
Manufacturing

BIO looks to re­struc­ture, lay­ing off staff amid chal­lenge to the trade org's nor­mal face-to-face style

5 years ago

Bio­Med Re­al­ty snaps up in­no­va­tion cam­pus site with­in earshot of pricey and bustling Boston biotech hub

5 years ago

Paul Hud­son faces down French unions in fight to re­struc­ture Sanofi

5 years ago

As­traZeneca keeps the ball rolling on Dai­ichi-part­nered En­her­tu, pick­ing up 2nd in­di­ca­tion in gas­tric can­cer

5 years ago
FDA+

Eli Lil­ly re-ups di­ver­si­ty pledge, pitch­ing in $30M to ven­ture fund for mi­nor­i­ty-owned health­care firms

5 years ago
Financing

Am­gen tops cost watch­dog's price gougers list based on 'un­sup­port­ed' in­creas­es for En­brel with­out mean­ing­ful da­ta

5 years ago

#JPM21: Al­bert Bourla pre­pares Pfiz­er to set­tle in to next phase post-Up­john, but that does­n't mean he's rul­ing out deals

5 years ago
People

What can a 157-year-old phar­ma gi­ant bring to the ta­ble of cell and gene ther­a­pies? Quite a bit, Bay­er says

5 years ago
Cell/Gene Tx

Sanofi has a name for its in­gre­di­ents spin­off, taps Cen­tri­ent head Karl Rot­thi­er as first CEO

5 years ago
First page Previous page 250251252253254255256 Next page Last page
A service from the Financial Times